Floatz logo

txa127

Acute Lymphoblastic Leukemia

Tarix PharmaceuticalsPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB
Daunorubicin
PETHEMA Foundation
Phase 4BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

txa127 is also rated in:

Double Cord Blood TransplantDormant
CC
Indicative ·
43 / 100
View asset →
Chronic Myelocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Non Hodgkins LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →